- Conditions
- Shoulder Pain
- Interventions
- Indirect MRA of shoulder, Gadopentetate Dimeglumine
- Procedure · Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Gadopentetate dimeglumine (Magnevist, BAY86-4882), Moxifloxacin (BAY12-8039), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Myocardial Infarction
- Interventions
- Magnevist (Gadopentetate dimeglumine, BAY86-4882)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 6
- States / cities
- San Diego, California • Winston-Salem, North Carolina • Tulsa, Oklahoma + 3 more
- Conditions
- Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
- Interventions
- FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose, Gadolinium-DTPA, Sunitinib
- Procedure · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Diagnostic Self Evaluation, Central Nervous System Diseases
- Interventions
- Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
- Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more
- Conditions
- CNS Lesion, Blood Brain Barrier Defect
- Interventions
- P03277, Gadobenate dimeglumine, MRI
- Drug · Device
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
- Conditions
- Magnetic Resonance Imaging
- Interventions
- Gadopentetate dimeglumine (Magnevist, BAY86-6661)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 2 Months to 23 Months
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 9
- States / cities
- San Diego, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Brain Disease
- Interventions
- MultiHance 0.1 mmol/kg, Dotarem, MultiHance 0.05 mmol/kg
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Stage A Adult Primary Liver Cancer (BCLC), Stage B Adult Primary Liver Cancer (BCLC)
- Interventions
- 3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
- Device · Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee